Cerebrolysin vs Methylene Blue
A side-by-side research comparison of Cerebrolysin and Methylene Blue across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | Methylene Blue |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | Methylene Blue (Methylthioninium Chloride) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | FDA-approved (off-label use) |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Acts as an alternative electron carrier in the mitochondrial electron transport chain, bypassing complex I-III blockades. Inhibits monoamine oxidase, tau aggregation, and provides antioxidant protection through auto-oxidation cycling. |
| Molecular weight | <10,000 Da (peptide fraction) | 319.85 Da |
| Half-life | 4-6 hours | 5-6.5 hours |
| Bioavailability | High (IM/IV) | ~72% oral |
| Typical dose | 5-30 mL | 0.5-2 mg/kg |
| Frequency | Daily for 10-20 days | Daily or cycled |
| Route | Intramuscular or IV | Oral solution or sublingual |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
Methylene Blue reported benefits
- Mitochondrial energy boost
- Cognitive enhancement
- Neuroprotection
- Anti-aging at cellular level
- Mood improvement
- Memory support
Related comparisons
Research and educational reference only. Not medical advice.